Design and in vitro evaluation of branched peptide conjugates: turning nonspecific cytotoxic drugs into tumor-selective agents.
The use of peptide receptors as targets for tumor-selective therapies was envisaged years ago with the findings that receptors for different endogenous regulatory peptides are overexpressed in several primary and metastatic human tumors, and can be used as tumor antigens. Branched peptides can retain or even increase, through multivalent binding, the biological activity of a peptide and are very resistant to proteolysis, thus having a markedly higher in vivo activity compared with the corresponding monomeric peptides. Oligo-branched peptides, containing the human regulatory peptide neurotensin (NT) sequence, have been used as tumor-specific targeting agents. These peptides are able to selectively and specifically deliver effector units, for cell imaging or killing, to tumor cells that overexpress NT receptors. Results obtained with branched NT conjugated to different functional units for tumor imaging and therapy indicate that branched peptides are promising novel multifunctional targeting molecules. This study is focused on the role of the releasing pattern of drug-conjugated branched NT peptides. We present results obtained with oligo-branched neurotensin peptides conjugated to 6-mercaptopurin (6-MP), combretastain A-4 (CA4) and monastrol (MON). Drugs were conjugated to oligo-branched neurotensin through different linkers, and the mode-of-release, together with cytotoxicity, was studied in different human cancer cell lines. The results show that branched peptides are very promising pharmacodelivery options. Among our drug-armed branched peptides, NT4-CA4 was identified as a candidate for further development and evaluation in preclinical pharmacokinetic and pharmacodynamic studies. This peptide-drug exhibits significant activity against pancreas and prostate human cancer cells. Consequently, this derivative is of considerable interest due to the high mortality rates of pancreas neuroendocrine tumors and the high incidence of prostate cancer.
Falciani
Chiara
C
Department of Molecular Biology, University of Siena, Via Fiorentina 1, 53100 Siena, Italy. chiarafalciani@unisi.it
Brunetti
Jlenia
J
Pagliuca
Chiara
C
Menichetti
Stefano
S
Vitellozzi
Lucia
L
Lelli
Barbara
B
Pini
Alessandro
A
Bracci
Luisa
L
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000633:toxicity; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D015122:Mercaptopurine / Q000138:chemical synthesis / Q000737:chemistry / Q000633:toxicity; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D009496:Neurotensin / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000633:toxicity; D010455:Peptides; D011743:Pyrimidines / Q000138:chemical synthesis / Q000737:chemistry / Q000633:toxicity; D018028:Receptors, Neurotensin / Q000037:antagonists & inhibitors / Q000378:metabolism; D013267:Stilbenes / Q000138:chemical synthesis / Q000737:chemistry / Q000633:toxicity; D013871:Thiones / Q000138:chemical synthesis / Q000737:chemistry / Q000633:toxicity
D000970:Antineoplastic Agents; D010455:Peptides; D011743:Pyrimidines; D018028:Receptors, Neurotensin; D013267:Stilbenes; D013871:Thiones; D009496:Neurotensin; C400223:monastrol; D015122:Mercaptopurine; C058728:fosbretabulin